Clinical trial NCT00920647
Conditions: Hunter Syndrome
Keywords: enlarged adenoids hunters syndrome enzyme replacement therapy hunter's syndrome mps society Mucopolysaccharidosis (mps) 2 mps diagnosis hunter disease iduronate 2 sulfatase idursulfase hunters disease hunter's syndrome treatment mucopolysaccharides hunter syndrome treatment Mucopolysaccharidosis (mps) ii elaprase hunter syndrome therapy lysosomal storage disease hunter's disease Mucopolysaccharidosis(MPS) II Mucopolysaccharidosis(MPS)2 hunter's disease treatment lysosomal storage disorder chronic ear infection mps symptoms iduronate sulfatase ert treatment
Sponsor: Shire
Start date: 2009-11-18; Completion date: 2012-10-29
Enrollment: 16 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Elaprase (idursulfase), a large molecular protein, is not expected to cross the blood brain barrier at therapeutic levels when administered intravenously. A new formulation of idursulfase, idursulfase-IT, that differs from that of the intravenous (IV) formulation, Elaprase, has been developed to be suitable for delivery into the cerebrospinal fluid (CSF) via intrathecal administration.

This Phase I/II study is designed to obtain necessary safety and exposure data, as well as secondary and exploratory outcome measures, to be interpreted and used in the design of subsequent clinical trials.

Detailed description:

Arms: arm 1: Untreated Patients arm 2: monthly using an intrathecal drug delivery device (IDDD) arm 3: monthly using an intrathecal drug delivery device (IDDD) arm 4: monthly using an intrathecal drug delivery device (IDDD)
Interventions: intervention 1: Control intervention 2: Idursulfase IT (1 mg) intervention 3: Idursulfase IT (10 mg) intervention 4: Idursulfase IT (30 mg)
Intervention descriptions: intervention 1: 3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT. intervention 2: The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month. intervention 3: Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month. intervention 4: Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.

Protocol documents: